Clinical Trials Logo

Therapeutic Equivalency clinical trials

View clinical trials related to Therapeutic Equivalency.

Filter by:

NCT ID: NCT06050343 Completed - Bioequivalence Clinical Trials

Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method

Start date: February 19, 2018
Phase: N/A
Study type: Interventional

Pharmacokinetics and pharmacodynamics of Rinsulin® R, injection solution, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, injection solution, 100 IU / ml (Lilly France ", France) using the euglycemic hyperinsulinemic clamp method.

NCT ID: NCT05786339 Completed - Clinical trials for Therapeutic Equivalency

Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects

Start date: November 17, 2018
Phase: Phase 1
Study type: Interventional

The bioavailability of Irbesartan (150 mg) developed by Shenzhen Haibin Pharmaceutical Co., Ltd. was compared with that of reference Irbesartan (Aprovel ®,150 mg) produced by Sanofi Clir SNC. The bioequivalence of single dose of test preparation and reference preparation was evaluated in heathy subjects under fasting and fed conditions.

NCT ID: NCT05282940 Completed - Clinical trials for Therapeutic Equivalency

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

Start date: February 26, 2022
Phase: Phase 1
Study type: Interventional

This study will investigate the bioavailability in women of 2 tablet formulations containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The study will be performed at a single site with 36 subjects. Participants will take 2 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.

NCT ID: NCT05225974 Completed - Clinical trials for Therapeutic Equivalency

A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects

Start date: July 16, 2021
Phase: Phase 1
Study type: Interventional

The study was designed as a single-site, randomized, open-label, crossover under fasted conditions. A single oral dose of 0.6 mg Liraglutide injection and Victoza® was given to the 32 healthy Chinese adult male volunteers.Blood samples were collected up to 72 h after administration.The primary pharmacokinetic endpoints were AUC0-t, AUC0-∞, and Cmax. Safety profile and immunogenicity data were collected from each subject.

NCT ID: NCT04885660 Completed - Clinical trials for Therapeutic Equivalency

Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects

Start date: October 12, 2018
Phase: Phase 1
Study type: Interventional

The bioavailability of compound lisinopril tablets (specification: lisinopril 10mg / amlodipine 5mg) developed by Sichuan shangrui biomedical Co., Ltd. was compared with that of reference compound lisinopril tablets (specification: lisinopril 10mg / amlodipine 5mg) produced by Hungary Gedeon Richter Pharmaceutical Co., Ltd.The bioequivalence of single dose of test preparation and reference preparation was evaluated in heathy subjects under fasting and fed conditions.

NCT ID: NCT04814589 Recruiting - Clinical trials for Therapeutic Equivalency

Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Start date: March 13, 2021
Phase: Phase 1
Study type: Interventional

According to the relevant provisions of bioequivalence test, ezetimibe Tablets (test preparation, T, 10mg / tablet) provided by China Resources Saike Pharmaceutical Co., Ltd. were compared with Ezetrol ® (reference preparation, R, 10mg / tablet) produced by MSD Pharma (Singapore) Pte. Ltd. to evaluate the bioequivalence of single dose in healthy subjects under fasting and fed conditions.

NCT ID: NCT04468282 Completed - Clinical trials for Therapeutic Equivalency

Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration

Start date: April 4, 2017
Phase: Phase 1
Study type: Interventional

Methodology: The study was an open label, randomized, crossover, 2 periods study in 20 healthy male/female volunteers. Subjects received 500 mg of the new formulation of soluble tablets vigabatrin or Sabril, as single oral administration in 2 different study periods depending on the randomization, with a 7-days wash out period between administrations

NCT ID: NCT04467346 Completed - Clinical trials for Therapeutic Equivalency

Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules

Start date: September 25, 2020
Phase: Phase 1
Study type: Interventional

Primary objective: • Evaluate bioequivalence between Temozolomide Oral Suspension and Temodal® capsules for oral administration. Secondary objectives: - Define the pharmacokinetic parameters of Temozolomide Oral Suspension. - Assess the buccal safety of Temozolomide Oral Suspension.

NCT ID: NCT04438720 Recruiting - Clinical trials for Therapeutic Equivalency

Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects

Start date: June 25, 2020
Phase: Phase 1
Study type: Interventional

According to the relevant provisions of bioequivalence test, nifedipine sustained-release tablets (test preparation, t, 30mg / tablet) provided by Guangzhou bostao controlled release pharmaceutical Co., Ltd. were compared with Adalat ® GITS (reference preparation, R, 30mg / tablet) produced by Bayer Pharma AG to evaluate the bioequivalence of single dose in healthy subjects under fasting conditions.

NCT ID: NCT03930264 Completed - Clinical trials for Therapeutic Equivalency

Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)

AZA
Start date: April 11, 2019
Phase: Phase 1
Study type: Interventional

A single center, single dose, open-label, randomized, two period crossover study to assess the bioequivalence of an oral azathioprine suspension 10 mg/mL (Jayempi™) versus oral azathioprine tablet 50mg (Imurek®, Aspen Pharma Trading Limited, Dublin, Ireland.) in at least 30 healthy adult subjects under fasting conditions.